NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer. Mr. Worsley has over 25 years of biotechnology...
Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment
Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat...
12th Biennial Ovarian Cancer Research Symposium – STRO-002 Poster
Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian Cancer
Sutro Biopharma Announces $85.4 Million Series E Round
Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its...
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and...
SutroVax Announces $85M Series C Financing led by TPG Growth
SutroVax Announces $85M Series C Financing led by TPG Growth Provides growth capital to advance pneumococcal vaccine to clinic and beyond Preeminent executive vaccinologist, Moncef Slaoui, appointed Board Chairman Strategic alignment established with Lonza Pharma...
American Society of Clinical Oncology (ASCO) 2018 – Poster
A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES, NCT03424603
Sutro CEO, Bill Newell appointed Chair of the California Life Sciences Association.
https://califesciences.org/california-life-sciences-association-elects-new-board-chair-adds-new-board-member/ California Life Sciences Association Elects New Board Chair, Vice Chair And Adds New Board Member SAN FRANCISCO, SACRAMENTO & SAN DIEGO, Calif., May 30,...
Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate, STRO-001, targeting CD74, a protein highly expressed in B-cell...
American Association for Cancer Research (AACR) 2018 – STRO-002 Poster
Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster Final